HC Wainwright Cuts Zynex (NASDAQ:ZYXI) Price Target to $8.00

Zynex (NASDAQ:ZYXI) had its price target decreased by HC Wainwright from $15.00 to $8.00 in a research note released on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Zynex’s Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.92) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.56) EPS.

A number of other analysts have also recently weighed in on ZYXI. LADENBURG THALM/SH SH cut shares of Zynex from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 12th. Royal Bank of Canada reissued a “sector perform” rating on shares of Zynex in a research report on Tuesday, April 15th.

Zynex Trading Up 14.9 %

NASDAQ:ZYXI opened at $2.31 on Wednesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company has a market capitalization of $69.82 million, a P/E ratio of 15.40 and a beta of 1.09. The stock’s 50 day moving average price is $3.35 and its 200 day moving average price is $6.47. Zynex has a 52 week low of $1.66 and a 52 week high of $11.81.

Zynex (NASDAQ:ZYXI) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). Zynex had a return on equity of 13.05% and a net margin of 2.49%. The business had revenue of $26.58 million during the quarter, compared to the consensus estimate of $30.83 million. On average, research analysts forecast that Zynex will post 0.2 EPS for the current fiscal year.

Insider Buying and Selling at Zynex

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.15, for a total transaction of $71,500.00. Following the completion of the transaction, the chief financial officer now owns 10,050 shares of the company’s stock, valued at approximately $71,857.50. This represents a 49.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 49.28% of the company’s stock.

Hedge Funds Weigh In On Zynex

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZYXI. Jane Street Group LLC grew its holdings in shares of Zynex by 8.9% during the 3rd quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock worth $192,000 after purchasing an additional 1,929 shares in the last quarter. Barclays PLC boosted its stake in Zynex by 43.3% during the third quarter. Barclays PLC now owns 28,821 shares of the company’s stock worth $236,000 after buying an additional 8,713 shares in the last quarter. Geode Capital Management LLC increased its holdings in Zynex by 6.7% in the 3rd quarter. Geode Capital Management LLC now owns 425,509 shares of the company’s stock valued at $3,473,000 after buying an additional 26,774 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Zynex by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company’s stock valued at $334,000 after buying an additional 1,318 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of Zynex by 10.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 159,259 shares of the company’s stock worth $1,276,000 after acquiring an additional 14,820 shares during the period. 29.68% of the stock is currently owned by institutional investors.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.